Alpelisib (BioDeep_00000858640)
代谢物信息卡片
Alpelisib
化学式: C19H22F3N5O2S (441.14462280000004)
中文名称: 阿培利司
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F
InChI: InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EM - Phosphatidylinositol-3-kinase (pi3k) inhibitors
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor
同义名列表
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:93752
- KEGGdrug: D11011
- PubChem: 56649450
- DrugBank: DB12015
- ChEMBL: CHEMBL2396661
- CAS: 1217486-61-7
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Sepehr Dehghani-Ghahnaviyeh, Cihan Soylu, Pascal Furet, Camilo Velez-Vega. Dissecting the Interaction Fingerprints and Binding Affinity of BYL719 Analogs Targeting PI3Kα.
The journal of physical chemistry. B.
2024 Feb; 128(8):1819-1829. doi:
10.1021/acs.jpcb.3c06766. [PMID: 38373112] - Yaya Yu, Zhenzhen Xiao, Chenjing Lei, Changju Ma, Lina Ding, Qing Tang, Yihan He, Yadong Chen, Xuesong Chang, Yanjuan Zhu, Haibo Zhang. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
BMC cancer.
2023 Aug; 23(1):732. doi:
10.1186/s12885-023-11243-0. [PMID: 37553597] - Yoshito Minami, Atsushi Hoshino, Yusuke Higuchi, Masahide Hamaguchi, Yusaku Kaneko, Yuhei Kirita, Shunta Taminishi, Toshiyuki Nishiji, Akiyuki Taruno, Michiaki Fukui, Zoltan Arany, Satoaki Matoba. Liver lipophagy ameliorates nonalcoholic steatohepatitis through extracellular lipid secretion.
Nature communications.
2023 07; 14(1):4084. doi:
10.1038/s41467-023-39404-6. [PMID: 37443159] - Christoph Suppan, Ricarda Graf, Stephan Jahn, Qing Zhou, Eva Valentina Klocker, Rupert Bartsch, Angelika Terbuch, Karl Kashofer, Peter Regitnig, Joerg Lindenmann, Florian Posch, Hanno Gerritsmann, Philipp J Jost, Ellen Heitzer, Nadia Dandachi, Marija Balic. Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.
British journal of cancer.
2022 02; 126(3):456-463. doi:
10.1038/s41416-021-01601-9. [PMID: 34754095] - Xiao Liu, Su Yang, Jonathan R Hart, Yingna Xu, Xinyu Zou, Huibing Zhang, Qingtong Zhou, Tian Xia, Yan Zhang, Dehua Yang, Ming-Wei Wang, Peter K Vogt. Cryo-EM structures of PI3Kα reveal conformational changes during inhibition and activation.
Proceedings of the National Academy of Sciences of the United States of America.
2021 11; 118(45):. doi:
10.1073/pnas.2109327118. [PMID: 34725156] - Giuseppe Curigliano, Miguel Martin, Komal Jhaveri, J T Beck, Giampaolo Tortora, Nicola Fazio, Michela Maur, Richard A Hubner, Harald Lahner, Valerie Donnet, Olga Ajipa, Zheng Li, Lars Blumenstein, Fabrice Andre. Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study.
European journal of cancer (Oxford, England : 1990).
2021 07; 151(?):49-62. doi:
10.1016/j.ejca.2021.03.042. [PMID: 33964572] - Christopher P Hedges, Jordi Boix, Jagdish K Jaiswal, Bhoopika Shetty, Peter R Shepherd, Troy L Merry. Efficacy of Providing the PI3K p110α Inhibitor BYL719 (Alpelisib) to Middle-Aged Mice in Their Diet.
Biomolecules.
2021 01; 11(2):. doi:
10.3390/biom11020150. [PMID: 33503847] - Seong-Wook Seo, Ji-Min Kim, Dong-Gyun Han, Dongho Geum, Hwayoung Yun, In-Soo Yoon. A sensitive HPLC-FLD method for the quantification of alpelisib, a novel phosphatidylinositol 3-kinase inhibitor, in rat plasma: Drug metabolism and pharmacokinetic evaluation in vitro and in vivo.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2021 Jan; 1163(?):122508. doi:
10.1016/j.jchromb.2020.122508. [PMID: 33387858] - Monika Gajewska, Lars Blumenstein, Alexandros Kourentas, Martin Mueller-Zsigmondy, Sebastien Lorenzo, Angela Sinn, Maria Velinova, Tycho Heimbach. Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection.
The AAPS journal.
2020 10; 22(6):134. doi:
10.1208/s12248-020-00511-7. [PMID: 33070288] - Abul K Azad, Pavel Zhabyeyev, Bart Vanhaesebroeck, Gary Eitzen, Gavin Y Oudit, Ronald B Moore, Allan G Murray. Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth.
Oncogene.
2020 10; 39(41):6480-6492. doi:
10.1038/s41388-020-01444-3. [PMID: 32879446] - Marine Berquez, Jonathan R Gadsby, Beatrice Paola Festa, Richard Butler, Stephen P Jackson, Valeria Berno, Alessandro Luciani, Olivier Devuyst, Jennifer L Gallop. The phosphoinositide 3-kinase inhibitor alpelisib restores actin organization and improves proximal tubule dysfunction in vitro and in a mouse model of Lowe syndrome and Dent disease.
Kidney international.
2020 10; 98(4):883-896. doi:
10.1016/j.kint.2020.05.040. [PMID: 32919786] - H S Rugo, F André, T Yamashita, H Cerda, I Toledano, S M Stemmer, J C Jurado, D Juric, I Mayer, E M Ciruelos, H Iwata, P Conte, M Campone, C Wilke, D Mills, A Lteif, M Miller, F Gaudenzi, S Loibl. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology.
2020 08; 31(8):1001-1010. doi:
10.1016/j.annonc.2020.05.001. [PMID: 32416251] - Diana G Wang, Dulce M Barrios, Victoria S Blinder, Jacqueline F Bromberg, Pamela R Drullinsky, Samuel A Funt, Komal L Jhaveri, Diana E Lake, Tomas Lyons, Shanu Modi, Pedram Razavi, Michelle Sidel, Tiffany A Traina, Linda T Vahdat, Mario E Lacouture. Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
Breast cancer research and treatment.
2020 Aug; 183(1):227-237. doi:
10.1007/s10549-020-05726-y. [PMID: 32613539] - Pedram Razavi, Maura N Dickler, Payal D Shah, Weiyi Toy, David N Brown, Helen H Won, Bob T Li, Ronglai Shen, Neil Vasan, Shanu Modi, Komal Jhaveri, Betty Ann Caravella, Sujata Patil, Pier Selenica, Stephen Zamora, Aimee M Cowan, Elizabeth Comen, Andy Singh, Anne Covey, Michael F Berger, Clifford A Hudis, Larry Norton, Rebecca J Nagy, Justin I Odegaard, Richard B Lanman, David B Solit, Mark E Robson, Mario E Lacouture, Edi Brogi, Jorge S Reis-Filho, Mary Ellen Moynahan, Maurizio Scaltriti, Sarat Chandarlapaty. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors.
Nature cancer.
2020 04; 1(4):382-393. doi:
10.1038/s43018-020-0047-1. [PMID: 32864625] - Neil Vasan, Pedram Razavi, Jared L Johnson, Hong Shao, Hardik Shah, Alesia Antoine, Erik Ladewig, Alexander Gorelick, Ting-Yu Lin, Eneda Toska, Guotai Xu, Abiha Kazmi, Matthew T Chang, Barry S Taylor, Maura N Dickler, Komal Jhaveri, Sarat Chandarlapaty, Raul Rabadan, Ed Reznik, Melissa L Smith, Robert Sebra, Frauke Schimmoller, Timothy R Wilson, Lori S Friedman, Lewis C Cantley, Maurizio Scaltriti, José Baselga. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.
Science (New York, N.Y.).
2019 11; 366(6466):714-723. doi:
10.1126/science.aaw9032. [PMID: 31699932] - Jordi Rodon, Giuseppe Curigliano, Jean-Pierre Delord, Wael Harb, Analia Azaro, Yu Han, Celine Wilke, Valerie Donnet, Dalila Sellami, Thaddeus Beck. A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.
Oncotarget.
2018 Aug; 9(60):31709-31718. doi:
10.18632/oncotarget.25854. [PMID: 30167089] - Alexander David James, Cyrille Marvalin, Alexandre Luneau, Axel Meissner, Gian Camenisch. Comparison of 19F NMR and 14C Measurements for the Assessment of ADME of BYL719 (Alpelisib) in Humans.
Drug metabolism and disposition: the biological fate of chemicals.
2017 08; 45(8):900-907. doi:
10.1124/dmd.117.075424. [PMID: 28566285] - Marco Falasca, Justin R Hamilton, Maria Selvadurai, Krithika Sundaram, Aleksandra Adamska, Philip E Thompson. Class II Phosphoinositide 3-Kinases as Novel Drug Targets.
Journal of medicinal chemistry.
2017 01; 60(1):47-65. doi:
10.1021/acs.jmedchem.6b00963. [PMID: 27644332] - Alexander James, Lars Blumenstein, Ulrike Glaenzel, Yi Jin, Arnold Demailly, Annamaria Jakab, Regine Hansen, Katharine Hazell, Anuradha Mehta, Lucia Trandafir, Piet Swart. Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers.
Cancer chemotherapy and pharmacology.
2015 Oct; 76(4):751-60. doi:
10.1007/s00280-015-2842-4. [PMID: 26254025] - Marian M Deuker, Victoria Marsh Durban, Wayne A Phillips, Martin McMahon. PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma.
Cancer discovery.
2015 Feb; 5(2):143-53. doi:
10.1158/2159-8290.cd-14-0856. [PMID: 25472943] - Stefan S De Buck, Annamaria Jakab, Markus Boehm, Douglas Bootle, Dejan Juric, Cornelia Quadt, Timothy K Goggin. Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies.
British journal of clinical pharmacology.
2014 Sep; 78(3):543-55. doi:
10.1111/bcp.12378. [PMID: 24617631]